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S_ry Thirty patients with symptomatic colorectal carcinoma were commenced on treatment with 5-
fluorouracil (2.5 g week-') adminid by continuous intravenous infusion and alpha 2b interferon (3 x 10'
U s.c. three times a week). Six out of 30 patients (20%) achieved a partial Tree patients (10%) had
stable disea and 21 patients (70%/) progressed on treatment. Twenty patients (67%) compited ten or more
weeks of treatment. In nine patients, treatment was withdrawn after 2-9 weeks because of diase progreson
or death. One patient's treatment was interupted by emergnc surgery. The medin survival for all patents
was 210 days (7 months). The principal side-ffects were oral mucositis (12/30 patients), nausea (8/30 patients)
and tansient diarrhoea (4/30 patients), and initial constitutional symptoms due to alpha 2b interferon. The
combination of low-dose continuous infusional 5-fluorouracil and low-dose alpha 2b interferon is wel
tolerated but has no obvious advantage over alternative infusional regimens using S-fluorouracil as a single
agent.
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Colorectal carcinoma affects 24 000 patients per year in Eng-
land and Wales (OPCS, 1986). Approximately 20% of these
individuals will have advanced metastatic disea at presenta-
tion, and a further 30% will develop metastases within 5
years of the initial diagnosis. The onset of metastases is
assocated with considerable morbidity, and most patients
will die of disease in the ensuing 6-18 months.
The mainstay of chemotherapeutic palliation is 5-
fluorouracil (5-FU). 5-FU is a pyrimidine antimetabolite
acting in the 'S' phase of the cell cycle (MacMillan et al.,
1978). The cytotoxic effects of 5-FU are mediated by active
metabolites which inhibit the synthesis of thymidine, DNA
and proteins (Ullman et al., 1978). The clinical effectiveness
of 5-FU is schedule dependent. Bolus regimens give con-
sistently poor results with response rates of 5-25% (Horton
et al., 1970; Siefert et al., 1975; Ansfield et al., 1977; Erlich-
man et al., 1988; Lokich et al., 1989). Response rates imp-
rove markedly when 5-FU is administered by i.v. infusion
over 5 days or by protracted i.v. infusion over a period of
many months (Siefert et al., 1975; Hartman et al., 1979;
Lokich et al., 1981; Nobile.et al., 1988; Petrelli et al., 1988;
Wade et al., 1988; Leichman et al., 1990; Poplin et al., 1991).
In an attempt to further improve results, 5-FU has been
used in combination with a number of anti-neoplastic agents
including alpha interferon. Synergism of alpha interferon and
5-FU has been demonstrated in vitro in various cell lines of
gastrointesinal origin, including several human colonic car-
cinoma cell lines (Wadler et al., 1990). Based on these results,
clinical trials have been established to evaluate the
effectiveness of alpha interferon and 5-FU in colorectal car-
cinoma in vivo (Wadler and Wiernik 1990). Subsequent
reports of a pharmacokinetic interaction between 5-FU and
alpha interferon which increases total exposure to 5-FU in
vivo also provide a rational basis for the combination (Grem
et al., 1991).
The phase II trials of combined 5-FU and alpha interferon
have produced encouraging results in untreated patients (res-
ponse rates 26-63%), (Fornasiero et al., 1990, Huberman et
al., 1990; Kemeny et al., 1990; Pazdur et al., 1990, Wadler et
al., 1991). Simila response rates (30-52%) have been
obtained in phase II trials of an alternative regimen using a
protracted continuous inusion of 5-FU as a single agent
(Ausman et al., 1985; Wade et al., 1988; Lokich et al.,
1989,1991; Findlay et al., 1993). The low toxicity recorded
with this regimen prompted us to examine the feasibility and
efficacy of combining continuous infusional 5-FU with alpha
interferon in patients with metastatic colorectal carcinoma.
Thirty individuals with metastatic colorectal carcinoma were
studied. Twehe patients had metastatic disease at the time of
initial diagnosis and 18 patients had relapsed after a com-
plete surgical clerance of apparently locahsed diseas. All
patients had at least one site of bidimensionally measurable
disease, were symptomatic and had a performance status of
1-3 on the WHO scale. Patients who had received no prior
chemotherapy and those previously treated with interleukin 3
or interieukin 6 in phase I trials were eligible. Patients
previously irradiated were included provided they had
measurable disease outside the radiation field. All patients
gave written informed consent and the study was conducted
with the approval of the Ethics Committee of South Man-
chester.
Pretreatment assessment included a medical history and
full physicl eamination, chest X-ray, CT scan of abdomen
and pelvis and baseline laboratory investigations (full blood
count and platelets, urea and ekctrolytes, liver function tests
and lactate dehydrogenase). Symptomatic patients com-
menced treatment within 1-2 weeks of referral. Asymp-
tomatic patients were reviewed at regular intervals and treat-
ment deferred until the onset of signciant symptoms. Treat-
ment was continued indefinitely beyond the 12 week assess-
ment if there was objective evidence of response or symp-
tomatic improvement.
5-FU was administered by continuous i.v. infusion via an
indwelling subclavian vein cannula, connected to a 7 day
reservoir of 5-FU in a CADD pump (Pharmacia). The initial
rate of infusion was 2.5 g per patient per week, increasing up
to 3.0 g per patient per week if well tolerted. The amount of
5-FU was caulated in g per patient per week to allow rapid
preparation and dispensing of filled CADD pumps and for
ease of dose adjustment. Dose adjustments were made at
weekly intervals and the maximum tolerated dose was estab-
lshed for each patient. In the event of signnt toxicity
(mucositis, hand-foot syndrome, diarrhoea or myelosuppres-
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sion) the infusion was interrupted until the symptoms and
signs of toxicity subsided and then reinstituted at the same
dose. If further toxicity occurred, the dose of 5-FU was
lowered by increments of 0.5 gweek'1. A minimum of 12
weeks' therapy was planned. Patients also received a fixed
dose of 3 x 106U of alpha 2b interferon (Intron A, Schering
Plough) given subcutaneously on 3 days of each week. Injec-
tions were usually given by a district nurse or self-
administered. Patients continued to receive full dose alpha 2b
interferon even when the 5-FU infuision was interrupted.
Patients attended weekly for pump change and were
examined at 2 weekly intervals. Blood tests were repeated
weekly. Radiological reassessment was performed at 12
weeks from the start of treatment.
Response and toxicity were recorded in accordance with
the UICC criteria. A complete response was defined as a
complete disappearance of all signs of active disease for a
minimum of4 weeks. A partial response required a reduction
of more than 50% in the sum of the products of the large
perpendicular axis of measurable lesions or a 50% decrease
in evaluable lesions. Progression was defined as a more than
25% increase in the size ofexisting measurable lesions or the
appearance of any new lesion and stabilisation if there was
no change which amounted to a partial response or progres-
sion.
Standard statistical measurements were used and Kap-
lan-Meier curves constructed to estimate survival.
Results
All 30 patients were evaluable for response, toxicity and
survival. The pretreatment characteristics of patients are
shown in Table I. The median age was 54 years. Overall, 14
parients had liver metastases, five had lung metastases and
seven had liver and lung metastases. Eight patients completed
the planned treatment without delay. A total of 20 patients
(67%) received 10 or more weeks of treatment. Nine patients
were withdrawn after 2-9 weeks of treatment because of
obvious progression or death, and one patient was admitted
for surgical repair of a gastrocolic fistula after 6 weeks.
Treatment was delayed for I or 2 weeks in eight patients and
for 3 or 4 weeks in four patients. The principal reasons for
treatment delay are shown in Table II.
When delays and dose reductions were taken into account.
the majority of patients (20/30) received between 1.5 and 2.9
g week' over 9-12 weeks. This was equivalent to a dose
range of 101-244 mgm-2day-' 5-fluorouracil (Table III).
The average dose was 170±23 mg m-2day-'. Only one
patient achieved the full dose of 3 gweek-'. Five patients
received an average of <0.9 gweek-' over the 12 week
period. In this group, treatment was stopped after 2-4 weeks
because of death or progressive disease. Four patients
received 1.1-1.4 gweek-1 (equivalent to 101-114
mgm-2day-) because treatment was curtailed by death,
surgery or toxicity after 5-9 weeks.
Response
Six out of 30 patients responded (20%). Three patients
(10%) had stable disease and 21 out of 30 (70%) progressed.
There were no complete responses. Taken by site of primary,
2/12 patients with rectal carcinoma achieved a partial res-
ponse (PR), whereas 4/18 with colonic carcinoma responded.
Three patients with rectal carcinoma had stable disease. The
median duration of progression-free survival for patients
achieving a PR or stable disease was 200 days (range
154-361 days).
Survival
Survival from the initiation of treatment was poor (Figure 1).
The median survival of all patients was 210 days (7 months).
Four patients were still alive at I year. Five patients died
within 40 days of starting treatment and a further four died
before the 3 month completion date. There was a trend for
improved survival among patients who achieved a PR or
stable disease at the 3 month assessment (range 9.3 to >21
months, median not yet reached) compared with those who
had progressive disease (median 6.3 months) (range 3.2-15.7)
(Figure 2). The overall survival was not affected by the site of
primary tumour (colon or rectal), site of metastases (liver,
lung, bone, other), number of sites involved or by initial
derangement in liver function tests (aspartate aminotrans-
Table I Pretreatment characteristics
30
54
30-70
16
14
No. of patients
Age (Years)
Median
Range
Sex
Male
Female
Primary site
Colon
Rectum
Sites of metastases
Liver
Lung
Liver and lung
Neither
Local abdominal mass
Bone
Other
No. sites of disease
1
2
3
>4
18
12
14
5
7
4
10
5
5
9
11
8
2
Table H Reasons for treatment delay
Cwnuative
No. ofpatients no. weeks delay,
Toxicity of 5-FU 5 11
Toxicity of alpha interferon 2 4
Central line problems 2 2
Infection 1 I
Hospital admission 1 3
for surgery
Low white cell count 1
Low platelets I I
Holiday/convenience 2 4
Total 15a 27
aAfurtherninepatientsfailed tocompletethe 12weekcoursebecauseof
progressive disease or death on treatment.
Table [ Average dose of 5-FU tolerated over the 12 week treatment period
Average dose over 12 weeks Range ofequivalent
(g perpatient week- ) No. ofpatients doses in mg m-2day'
<0.9 5 25-56
1.0-14.0 4 104-114
1.5-1.9 9 101-172
2.0-2.4 6 159-188
2.5-2.9 5 188-244
3.0-3.4 1 236100
90
80
70
60
50
40
30
20
10
0.0 0.5 1.0
Years
1.5 2.0
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Table IV Incidence oftoxic effects (n = 30 patients)
No. ofpatients
WHO grade WHO grade
1-2 3-4
Attributable to 5-IFU 12 0
Nausea 8 0
Diarrhoea 4 0
Palmer/plantar erythema 3 0
Oral mucositis 12 0
Oral candidiasis 5 0
Other infection 3 0
Neutropenia 0 1
Thrombocytopenia 0 1
Attnrbutable to alpha IFN
Flu-like symptoms 10 I
Fatigue 5 1
Fevers 1 I
Somnolence 1 I
Fgure 1 Survival of all patients treated with 5-fluorouracil and
alpha interferon (n = 30, median survival = 7months).
one patient treatment was delayed 1 week because of throm-
bocytopenia (platelet count 47 x 10Or 1-'), but treatment was
subsequently completed at the same dose level without fur-
ther incident. Two patients required blood transfusions for
occult gastrointestinal haemorrhage. One patient required
emergency surgery for a gastrocolic fistula.
am 0X
o
. _
70
60
50
40 -
30-
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0.0
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FJigue 2 Survival of patients alive 3 months al
response achieved (partial response (PR) + stal
n = 8; disease progression (PD), n = 12). Patients
completion of the initial trial period of 3 montd
(n = 9), as was one patient whose treatment wa
surgery.
ferase, alkaline phosphatase, a-glutamyltrans
dehydrogenase values. Survival of patients
and recurrent disease was similar.
Toxicity,
The combination of 5-FU and alpha inte
tolerated and there were no treatment-relate
IV shows the incidence of toxic effects. On
common (12/30 patients), mild to modei
(WHO grade 1-2) and frequently accom
didiasis (5/30 patients). Overall, oral mucosil
cipal reason for treatment delay and dose re
reporting nausea (8/30 patients) or transient
patients) responded to simple medication. P
tar erythema/exfoliation was uncommon (3/.
no specific treatment was required. Toxic eff
to alpha interferon (flu-like symptoms, fa
nolence) were frequently reported at the st-
but diminished with time. Alpha interferon w
6 weeks in one patient because of persisi
symptoms. Haematological toxicity was ra
developed abrupt neutropenia (WBC 0.7 x I
pleted treatment at a reduced dose after a 1
+ SD (n = 8)
We report a disappointingly low response rate (overall res-
ponse 20%) to continuous infusional 5-FU in combination
with alpha interferon in patients with metastatic colorectal
carcinoma. Previous studies using these agents (continuous
infusional 5-FU alone or alpha interferon and 5 day
infusions of 5-FU) have reported very variable results
)(n- 14)
(30-53% and 26-63% response
rates respectively) (Leich-
man et al., 1985; Wade et al., 1988; Kenemy et al., 1990;
1.5 2.0 Wadler and Weirnik, 1990; Lokich et al., 1991; Wadler et al., 1991). Overall, our response rates were the lowest recorded.
This apparent inconsistency may be explained in part by
fter treatment by sampling error inherent in trials involving small numbers of
ble disease (SD), patients, and by variation in tumour measurement
who died before methodology and in the degree of stringency in application
hs were excluded of response criteria, particularly when there are liver or lung
is interrpted by metastases. In this trial, only objective radiological criteria
were used and the UICC response criteria were rigidly app-
lied.
In direct contrast to previous studies, we elected to treat
patients only when they became symptomatic. Inevitably, this
sferase or lactate included some patients with large tumour burdens and dec-
with advanced lining performance status, some of whom rapidly entered the
terminal phase within a few weeks of starting treatment and
died before completing the 3 month course (9/30 patients).
By excluding asymptomatic patients, we may have selected a
subgroup of patients with more advanced disease and a low
rferon was well potential for tolerating and responding to treatment. Thus,
ad deaths. Table our results may not be strictly comparable to other trials
al mucositis was which included asymptomatic and/or minimally symptomatic
rate in severity patients.
ipanied by can- Two studies provide evidence for inferior responses to
tis was the prin- treatment and survival among symptomatic patients. Grem et
duction. Patients al. (1991) reported a significantly lower response rate among
diarrhoea (4/30 patients with ECOG grade II symptoms (33%) than among
'almar and plan- asymptomatic or minimally symptomatic patients (53%)
30 patients) and treated with the same regimen. The Nordic Gastrointestinal
fects attributable Tumour Adjuvant Therapy Group (1992) found that the
tigue and som- median survival, asymptomatic phase and time to disease
art of treatment progression may be improved by as much as 6 months by
ias stopped after early treatment of asymptomatic patients. However, treating
tent and severe all patients in the asymptomatic phase would be a large
.re. One patient clinical undertaking and does not take into account the
0o61-1) but com- variable course of metastatic carcinoma of the colon. At one
week delay. In end of the disease spectrum there are patients who become
0-
cn
o
cn
100
90
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JE Ferguson etal
196
symptomatic and rapidly enter the terminal phase, whereas
others may be asymptomatic or minimally symptomatic for
long periods of time from the diagnosis of metastases
(53-621 days in our series) and continue to have a prolonged
clinical course in the symptomatic phase. Clearly, it is essen-
tial to identify reliable prognostic criteria which would aid
selection of those patients most likely to benefit from early
treatment and those for whom expectant treatment would be
more appropriate.
Two additional factors which may have compromised our
response rates are the low doses of 5-FU and alpha
interferon administered. The intended dose of 5-FU in most
studies using single-agent infusional 5-FU is 300
mg m-2 day-'. with dose reductions to 250-200
mg m- day' in the event of toxic effects. Our patients
commenced at 2.5 gweek'. and half (15,/30) required subse-
quent dose reduction. The majority received an average of
1.5-2.9 gweek-'. This dose is equivalent to 101-244
mgm2 day-', and the average dose received (170
mgm2 day-1) is clearly well below the doses tolerated in
other studies using 5-FU alone. The dose-limiting side-effect
was oral mucositis and, to a lesser extent, nausea and diarr-
hoea.
Although WHO grade 3-4 mucositis did not occur, we
found that persistent mild mucositis was poorly tolerated
over the long treatment period and precluded subsequent
dose escalations.
We used a fixed low dose of alpha interferon
(3 x 106U x three times a week) with the initial intent of
maximising the dose of the primary active agent, 5-FU. The
clinical effect of alpha interferon on colorectal carcinoma
trials does not appear to be dose related. More responses
have been reported with 5-FU in combination with low doses
of alpha interferon compared with high doses: five out of
nine patients treated with 6 or 9 x 106U responded compared
with none treated with 12, 15 or 18 x 10U x three times a
week (Wadler et al., 1990) and 4/9 and 4/7 treated with 3 and
5 x 10U m-' daily, respectively, compared with 2/6 treated
at 10 x 10% m- daily (Grem et al., 1991). By contrast, toxic
effects appear to increase with increasing doses of alpha
interferon. When compared with high doses of alpha
interferon, low-dose regimens (3 or 5 x 10U m-2 daily) are
associated with a lower incidence of severe mucositis, CNS
toxicity and a lower requirement for dose reduction of 5-FU
(Grem et al., 1991). However, the dose of 5-FU tolerated by
most of our patients (101-244 mg m-2day-') was lower
than that tolerated by others treated with single-agent con-
tinuous infusional 5-FU (200-300 mg m-2 day-'), suggesting
that even 3 x 106U of alpha interferon three times a week
may increase the toxicity of 5-FU (Lokich et al., 1989, 1991;
Wadler et al., 1991; Findlay et al., 1993). This finding cor-
roborates those of Meadows et al. (1991), who reported an
increase in mucositis and a low actual dose of 5-FU delivered
(160 mgm-2day-) with doses of alpha interferon in excess
of 2 x 106 U m-2 three times a week in patients with gast-
rointestinal tumours. Similarly, in a study by Grem et al.
(1991), addition of alpha interferon reduced the maximum
tolerated dose of 5-FU.
This phenomenon may be due in part to the phar-
makokinetic and biochemical interactions between the two
agents. At doses of 5 and 10 x 106 Um2 day-', alpha
interferon increases the total exposure of 5-FU by increasing
the half-life and reducing its clearance (Grem et al., 1991).
Additional clinical and toxic effects may be due to the syner-
gistic biochemical interaction of 5-FU and alpha interferon
on the inhibition of thymidylate synthetase which has been
demonstrated in preclinical studies. A recent clinical study
using magnetic resonance spectroscopy to monitor the
metabolism of 5-FU provides evidence for biomodulation in
vivo: addition of alpha interferon increased the accumulation
of 5-FU in responsive tumours and was associated with the
appearance of new cytotoxic anabolites not found with
single-agent 5-FU (Findley et al., 1993).
In this study, we found no evidence of clinically beneficial
chemomodulation of 5-FU by alpha interferon. However, as
the continuous infusional 5-FU was extremely well tolerated
and some patients may have received suboptimal doses, we
plan to further assess its efficacy as a single agent given to
dose-limiting toxicity over long periods of time in symp-
tomatic patients. As a potentially large number of patients
may be eligible for treatment each year, the feasibility of
community-based care is being studied in parallel.
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